Healthcare Stocks To Buy According To Lee Ainslie’s Maverick Capital


It wasn’t long before Lee Ainslie founded Maverick Capital in 1993 at the age of 28. He has watched the hedge fund’s portfolio grow from a few million dollars to billions of dollars over the years. It has become one of the world’s largest investment funds of its kind. Mr. Ainslie previously worked at the New York-based hedge fund Tiger Management before starting Maverick Capital. Microsoft,, and Meta Platforms, Inc. are a few of the well-known names in his portfolio.

Insider Monkey highlights the ten healthcare stocks to buy according to Lee Ainslie’s Maverick Capital. The United Kingdom-based LivaNova PLC designs and manufactures cardiovascular and neuromodulation devices. Customers can use the company’s products to repair heart valves and administer nerve stimulation therapy, among other applications. Biotechnology-based gene therapies for children with serious diseases are the focus of Rocket Pharmaceuticals, Inc. Bone marrow defects, immune system issues, anemia, and infantile osteoporosis can all be treated with its products. When Curis, Inc. reported revenue of $3 million and GAAP EPS of -$0.12 in the third fiscal quarter, the company beat analysts’ expectations. Lymphoma and solid tumors are among the diseases that the company’s treatments are designed to treat. With 4.3 million shares worth $1.7 billion, Harris Associates of Natixis Global Asset Management is Humana’s largest shareholder. From $559 in December 2021, Morgan Stanley lowered the healthcare provider’s price target by $70 to $530. For more details, click 10 Healthcare Stocks To Buy According To Lee Ainslie’s Maverick Capital.